The American Association of Clinical Endocrinology and the American Diabetes Association recommend GLP-1 RAs for patients with T2DM who have chronic kidney disease, atherosclerotic cardiovascular disease risk, or obesity [6, 7]. This evidence concerns the gene GCG and diabetes mellitus.